Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
Healthcare
$22.98 +0.34%
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
52W Low $2.45High $38.33
Volume 0.58M
Average 0.33M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$210.87M
FY 2025 · Annual
Net Income
-$209.84M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 441K | 490K | 830K | 181K | 0 |
| Gross Profit | (441K) | (490K) | (830K) | (181K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.49M | 48.21M | 23.77M | 6.4M | 201.19M |
| Selling, General & Admin | 13.3M | 12.51M | 11.86M | 10.32M | 9.69M |
| Operating Expenses | 51.79M | 60.72M | 35.63M | 16.72M | 210.87M |
| Depreciation & Amortization | 441K | 490K | 830K | 181K | 34K |
| EBITDA | (51.31M) | (61.13M) | (37.52M) | (21.22M) | (209.76M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (52.23M) | (61.21M) | (36.46M) | (16.9M) | (210.87M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 156K | 722K | 1.69M | 844K | 1.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 475K | (417K) | (1.89M) | (4.5M) | 1.08M |
| Income Before Tax | (51.75M) | (61.62M) | (38.35M) | (21.4M) | (209.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 41K | 50K |
| Net Income | (51.75M) | (61.62M) | (38.35M) | (21.44M) | (209.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| EPS (Diluted) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| 1.01M | 1.02M | 1.06M | 1.16M | 1.33M | |
| 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
DMRA Earnings Waterfall · TTM
NASDAQ:DMRA · Revenue to Net Income
Key Ratios
EPS$-177.17
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-0.3
P/S Ratio0.0
Analysis
$0 of revenue converted into -$235.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-177.17, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 13, 2026 | |
| 3 | Initial statement of beneficial ownership | Aug 13, 2026 | |
| EFFECT | EFFECT filing | Aug 12, 2026 |
How much revenue does DMRA generate?
Damora Therapeutics, Inc. (DMRA) reported $0.00 of revenue in fiscal 2025.
Is DMRA profitable?
Damora Therapeutics, Inc. (DMRA) reported -$209.84M of net income.
Continue the stock analysis
Jump to another research area for this company.